Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers
Traditional polymeric nanoparticle formulations for prolonged local action during inhalation therapy are highly susceptible to muco-ciliary clearance. In addition, polymeric carriers are typically administered in high doses due to finite drug loading. For toxicological reasons, these carriers and their degradation byproducts are undesirable for inhalation therapy, particularly for chronic use, due to potential lung accumulation.
We synthesized a novel, insoluble prodrug (MRPD) of a time-dependent β-lactam, meropenem, and formulated MRPD into mucus-penetrating crystals (MRPD-MPCs). After characterizing their mucus mobility (in vitro) and stability, we evaluated the lung pharmacokinetics of intratracheally-instilled MRPD-MPCs and a meropenem solution in guinea pigs.
Meropenem levels rapidly declined in the lungs of guinea pigs receiving meropenem solution compared to those given MRPD-MPCs. At 9 h after dosing, drug levels in the lungs of animals that received meropenem solution dropped to 12 ng/mL, whereas those that received MRPD-MPCs maintained an average drug level of ≥1,065 ng/mL over a 12-h period.
This work demonstrated that the combination of prodrug chemistry and mucus-penetrating platform created nanoparticles that produced sustained levels of meropenem in guinea pig lungs. This strategy represents a novel approach for sustained local drug delivery to the lung without using encapsulating matrices.
KEY WORDSantibiotics drug delivery meropenem mucus nanoparticle prodrug
Human lung microsomes
High-performance liquid chromatography
Luminal mucus layer
Minimum inhibitory concentration
Methoxy poly(ethylene) glycol
MRPD formulated as a mucus-penetrating crystal
Mean ensemble velocity
- 4.Wolff RK, Griffith WC, Jr., Cuddihy RG, Snipes MB, Henderson RF, Mauderly JL, et al. Modeling accumulations of particles in lung during chronic inhalation exposures that lead to impaired clearance. Health Phys. 1989;57 Suppl 1 (Copyright (C) 2015 U.S. National Library of Medicine.):61–7; discussion 7–8.Google Scholar
- 11.Yang M, Yu T, Wang YY, Lai SK, Zeng Q, Miao B, et al. Vaginal Delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater. 2013.Google Scholar
- 16.Popov A, Enlow EM, Bourassa J, Gardner CR, Chen H, Ensign LM, et al. Nanocrystals, compositions, and methods that aid particle transport in mucus. US Patent Application Publication. 2013; US20130323179.Google Scholar
- 18.Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46(8):2327–32.PubMedCentralCrossRefPubMedGoogle Scholar
- 24.Cayston prescribing information. Available from: http://www.cayston.com/prescribing_info.html as of August, 2014.
- 28.Cystic Fibrosis Foundation Patient Registry 2008 Annual Data Report. Bethesda: Cystic Fibrosis Foundation 2009.Google Scholar
- 30.Maiz L, Giron RM, Olveira C, Quintana E, Lamas A, Pastor D, et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother. 2013;14(9):1135–49.CrossRefPubMedGoogle Scholar